Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Symbol: NYSE:NVRO
- CUSIP: N/A
- Web: www.nevro.com
Capitalization:- Market Cap: $2.16 billion
- Outstanding Shares: 29,295,000
Average Prices:- 50 Day Moving Avg: $83.97
- 200 Day Moving Avg: $85.88
- 52 Week Range: $66.55 - $106.93
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 820.44
- P/E Growth: -2.99
Sales & Book Value:- Annual Revenue: $255.29 million
- Price / Sales: 8.47
- Book Value: $8.29 per share
- Price / Book: 8.91
Profitability:- EBIDTA: ($25,290,000.00)
- Net Margins: -18.91%
- Return on Equity: -14.57%
- Return on Assets: -9.98%
Debt:- Debt-to-Equity Ratio: 0.55%
- Current Ratio: 11.83%
- Quick Ratio: 9.71%
Misc:- Average Volume: 579,954 shs.
- Beta: -0.75
- Short Ratio: 10.75
Frequently Asked Questions for Nevro Corp (NYSE:NVRO)
What is Nevro Corp's stock symbol?
Nevro Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro Corp's earnings last quarter?
Nevro Corp (NYSE:NVRO) released its earnings results on Monday, May, 8th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.24. The company had revenue of $68.40 million for the quarter, compared to the consensus estimate of $68.71 million. Nevro Corp had a negative net margin of 18.91% and a negative return on equity of 14.57%. The firm's revenue was up 64.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.33) earnings per share. View Nevro Corp's Earnings History.
Where is Nevro Corp's stock going? Where will Nevro Corp's stock price be in 2017?
13 brokerages have issued 1-year price objectives for Nevro Corp's shares. Their forecasts range from $85.00 to $120.00. On average, they expect Nevro Corp's stock price to reach $101.90 in the next year. View Analyst Ratings for Nevro Corp.
What are analysts saying about Nevro Corp stock?
Here are some recent quotes from research analysts about Nevro Corp stock:
- 1. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (5/11/2017)
- 2. Northland Securities analysts commented, "The widely awaited release of Boston Scientific's ACCELERATE Study data on the Q4 call today, was a downer. Strangely enough, the company stated on its call that it "would continue enrolling patients in the trial, expects enrollment to finish by end of FY17, and data release by mid-2018." Suffice it to say, the anti-climax will be perceived as something being off in the ACCELERATE Study, hence being positive for Nevro."The analyst speculated that something is off in the ACCELERATE study, causing a delay in datarelease. Here are some thoughts / questions:Is Boston Sci increasing the sample size in the trial ?Was there a sub-group analysis done and investigators realized that the bellcurve on lead placements was not on T8 - T10 locations, hence pain relief was sub-optimal? Will there now be more anatomical placement on T8 - T10 with its HF arm? In essence, is Boston Sci converging on Nevro's "secret sauce" (2/2/2017)
Who are some of Nevro Corp's key competitors?
Some companies that are related to Nevro Corp include NuVasive (NUVA), Globus Medical (GMED), Wright Medical Group (WMGI), NxStage Medical (NXTM), CONMED (CNMD), MiMedx Group (MDXG), Integer Holdings (ITGR), Spectranetics Corp (SPNC), Natus Medical (BABY), Novocure Ltd (NVCR), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO), Orthofix International NV (OFIX), Intersect ENT (XENT), Lantheus Holdings (LNTH), GenMark Diagnostics (GNMK), Cryolife (CRY) and AxoGen (AXGN).
Who owns Nevro Corp stock?
Nevro Corp's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (7.55%), Vanguard Group Inc. (6.63%), BlackRock Inc. (5.40%), Goldman Sachs Group Inc. (5.07%), Alliancebernstein L.P. (4.19%) and OppenheimerFunds Inc. (2.64%). Company insiders that own Nevro Corp stock include & Johnson Johnson, Andre Walker, Andrew H Galligan, Bay City Capital Llc, Brad Vale, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro Corp.
Who sold Nevro Corp stock? Who is selling Nevro Corp stock?
Nevro Corp's stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY, FMR LLC, Next Century Growth Investors LLC, Alliancebernstein L.P., American Century Companies Inc., Wellington Management Group LLP, Artisan Partners Limited Partnership and Kornitzer Capital Management Inc. KS. Company insiders that have sold Nevro Corp stock in the last year include Andre Walker, Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Insider Buying and Selling for Nevro Corp.
Who bought Nevro Corp stock? Who is buying Nevro Corp stock?
Nevro Corp's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., Perceptive Advisors LLC, Janus Capital Management LLC, OppenheimerFunds Inc., Gilder Gagnon Howe & Co. LLC, Columbus Circle Investors and Blue Jay Capital Management LLC. View Insider Buying and Selling for Nevro Corp.
How do I buy Nevro Corp stock?
Shares of Nevro Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Nevro Corp stock cost?
One share of Nevro Corp stock can currently be purchased for approximately $73.84.
Earnings History for Nevro Corp (NYSE:NVRO)Earnings History by Quarter for Nevro Corp (NYSE:NVRO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q1 2017 | ($0.26) | ($0.50) | $68.71 million | $68.40 million | View | Listen |  |
| 2/23/2017 | Q416 | ($0.20) | ($0.34) | $66.41 million | $70.50 million | View | N/A | |
| 11/7/2016 | Q316 | ($0.39) | ($0.14) | $58.05 million | $60.92 million | View | Listen | |
| 8/8/2016 | Q216 | ($0.47) | ($0.31) | $45.11 million | $55.40 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.65) | ($0.33) | $33.48 million | $41.65 million | View | N/A | |
| 2/29/2016 | Q415 | ($0.56) | ($0.51) | $32.88 million | $33.10 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.75) | ($0.70) | $12.51 million | $15.40 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.89) | ($0.77) | $9.65 million | $11.40 million | View | N/A | |
| 5/11/2015 | Q1 | ($0.54) | ($0.57) | $8.20 million | $9.66 million | View | Listen | |
| 3/18/2015 | Q4 2014 | ($0.51) | ($0.59) | | $9.72 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Nevro Corp (NYSE:NVRO)Current Year EPS Consensus Estimate: $-0.99 EPS
Next Year EPS Consensus Estimate: $0.09 EPS
Dividend History for Nevro Corp (NYSE:NVRO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Nevro Corp (NYSE:NVRO)Insider Ownership Percentage: 12.10%
Insider Trades by Quarter for Nevro Corp (NYSE:NVRO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/15/2017 | Andrew H. Galligan | CFO | Sell | 7,500 | $75.30 | $564,750.00 | |
| 5/2/2017 | Michael F Demane | Director | Sell | 29,800 | $96.07 | $2,862,886.00 | |
| 5/1/2017 | Rami Elghandour | CEO | Sell | 10,000 | $95.03 | $950,300.00 | |
| 4/4/2017 | Michael Enxing | VP | Sell | 1,500 | $93.53 | $140,295.00 | |
| 4/4/2017 | Michael F Demane | Director | Sell | 22,200 | $93.39 | $2,073,258.00 | |
| 4/3/2017 | Andrew H. Galligan | CFO | Sell | 30,000 | $94.46 | $2,833,800.00 | |
| 3/6/2017 | Michael Enxing | VP | Sell | 38,500 | $91.01 | $3,503,885.00 | |
| 3/3/2017 | Wilfred E Jaeger | Director | Sell | 43,980 | $95.03 | $4,179,419.40 | |
| 1/4/2017 | Michael Enxing | VP | Sell | 1,500 | $75.88 | $113,820.00 | |
| 12/5/2016 | Michael Enxing | VP | Sell | 1,500 | $76.38 | $114,570.00 | |
| 11/15/2016 | Andrew H Galligan | CFO | Sell | 7,500 | $86.90 | $651,750.00 | |
| 10/10/2016 | Rami Elghandour | CEO | Sell | 3,000 | $100.00 | $300,000.00 | |
| 10/6/2016 | Michael F Demane | Director | Sell | 139,514 | $97.46 | $13,597,034.44 | |
| 10/4/2016 | Michael Enxing | VP | Sell | 1,500 | $99.31 | $148,965.00 | |
| 8/22/2016 | Doug Alleavitch | VP | Sell | 3,000 | $100.00 | $300,000.00 | |
| 8/22/2016 | Wilfred E Jaeger | Director | Sell | 154,840 | $97.79 | $15,141,803.60 | |
| 8/17/2016 | Wilfred E Jaeger | Director | Sell | 155,160 | $97.31 | $15,098,619.60 | |
| 8/15/2016 | Andrew H Galligan | CFO | Sell | 7,500 | $97.71 | $732,825.00 | |
| 8/10/2016 | Doug Alleavitch | VP | Sell | 2,500 | $95.00 | $237,500.00 | |
| 8/9/2016 | Michael F Demane | Director | Sell | 26,667 | $91.50 | $2,440,030.50 | |
| 8/4/2016 | Michael Enxing | VP | Sell | 1,500 | $82.06 | $123,090.00 | |
| 7/29/2016 | Doug Alleavitch | VP | Sell | 1,000 | $85.00 | $85,000.00 | |
| 7/29/2016 | Michael F Demane | Director | Sell | 13,333 | $84.00 | $1,119,972.00 | |
| 7/11/2016 | Doug Alleavitch | VP | Sell | 2,000 | $80.00 | $160,000.00 | |
| 7/11/2016 | Michael F Demane | Director | Sell | 13,333 | $79.00 | $1,053,307.00 | |
| 7/5/2016 | Michael Enxing | VP | Sell | 1,500 | $75.39 | $113,085.00 | |
| 7/1/2016 | Michael F Demane | Director | Sell | 13,333 | $74.00 | $986,642.00 | |
| 6/8/2016 | Doug Alleavitch | VP | Sell | 1,000 | $75.00 | $75,000.00 | |
| 6/8/2016 | Rami Elghandour | CEO | Sell | 7,000 | $76.59 | $536,130.00 | |
| 6/6/2016 | Michael Enxing | VP | Sell | 1,500 | $73.29 | $109,935.00 | |
| 6/2/2016 | Andre Walker | VP | Sell | 4,000 | $73.50 | $294,000.00 | |
| 6/1/2016 | Doug Alleavitch | VP | Sell | 500 | $72.00 | $36,000.00 | |
| 5/18/2016 | Wilfred E Jaeger | Director | Sell | 112,983 | $64.68 | $7,307,740.44 | |
| 5/16/2016 | Andrew H Galligan | CFO | Sell | 10,000 | $64.78 | $647,800.00 | |
| 5/16/2016 | Michael F Demane | CEO | Sell | 39,999 | $64.77 | $2,590,735.23 | |
| 5/12/2016 | Rami Elghandour | President | Sell | 7,000 | $63.93 | $447,510.00 | |
| 5/4/2016 | Michael Enxing | VP | Sell | 1,500 | $65.06 | $97,590.00 | |
| 4/4/2016 | Michael Enxing | VP | Sell | 8,767 | $61.59 | $539,959.53 | |
| 4/1/2016 | Rami Elghandour | President | Sell | 7,000 | $60.99 | $426,930.00 | |
| 1/11/2016 | Andre Walker | VP | Sell | 7,987 | $70.75 | $565,080.25 | |
| 1/4/2016 | Doug Alleavitch | VP | Sell | 2,514 | $66.47 | $167,105.58 | |
| 12/17/2015 | Andre Walker | VP | Sell | 13 | $69.00 | $897.00 | |
| 12/7/2015 | Rami Elghandour | President | Sell | 3,500 | $61.82 | $216,370.00 | |
| 12/2/2015 | Andre Walker | VP | Sell | 1,000 | $64.00 | $64,000.00 | |
| 12/1/2015 | Andre Walker | VP | Sell | 8,000 | $59.50 | $476,000.00 | |
| 11/30/2015 | Andre Walker | VP | Sell | 6,000 | $58.50 | $351,000.00 | |
| 11/30/2015 | Rami Elghandour | President | Sell | 3,500 | $60.00 | $210,000.00 | |
| 11/24/2015 | Andre Walker | VP | Sell | 1,000 | $55.00 | $55,000.00 | |
| 11/23/2015 | Andre Walker | VP | Sell | 1,000 | $54.00 | $54,000.00 | |
| 11/23/2015 | Wilfred E Jaeger | Director | Sell | 25,000 | $53.48 | $1,337,000.00 | |
| 11/18/2015 | Wilfred E Jaeger | Director | Sell | 175,000 | $52.24 | $9,142,000.00 | |
| 11/16/2015 | Michael F Demane | CEO | Sell | 26,667 | $50.52 | $1,347,216.84 | |
| 11/13/2015 | Brad Vale | Director | Buy | 2,000 | $50.76 | $101,520.00 | |
| 9/17/2015 | Andre Walker | VP | Sell | 4,000 | $50.75 | $203,000.00 | |
| 9/2/2015 | Michael F Demane | CEO | Sell | 40,001 | $45.11 | $1,804,445.11 | |
| 6/8/2015 | & Johnson Johnson | Major Shareholder | Sell | 1,010,265 | $47.94 | $48,432,104.10 | |
| 6/8/2015 | Bay City Capital Llc | Insider | Sell | 491,835 | $47.94 | $23,578,569.90 | |
| 6/8/2015 | Wilfred E Jaeger | Director | Sell | 393,468 | $47.94 | $18,862,855.92 | |
| 11/12/2014 | & Johnson Johnson | Major Shareholder | Buy | 40,000 | $18.00 | $720,000.00 | |
| 11/12/2014 | A/S Novo | Insider | Buy | 215,000 | $18.00 | $3,870,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Nevro Corp (NYSE:NVRO)
Latest Headlines for Nevro Corp (NYSE:NVRO)
| Source: |
|
| Date | Headline |
|---|
 | Nevro Corp (NVRO) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - May 24 at 3:56 PM |
| Zacks: Analysts Anticipate Nevro Corp (NVRO) Will Announce Quarterly Sales of $73.83 Million
www.americanbankingnews.com - May 17 at 12:02 PM |
| Nevro Corp (NVRO) CFO Sells $564,750.00 in Stock
www.americanbankingnews.com - May 16 at 7:33 PM |
| -$0.28 EPS Expected for Nevro Corp (NVRO) This Quarter
www.americanbankingnews.com - May 15 at 9:24 AM |
| B. Riley Downgrades Nevro Corp (NVRO) to Neutral
www.americanbankingnews.com - May 14 at 10:16 AM |
| Nevro Corp (NVRO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 7:40 AM |
| Nevro Corp (NVRO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 11 at 8:04 AM |
 | Edited Transcript of NVRO earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 11:59 AM |
 | Oversold Conditions For Nevro (NVRO)
www.nasdaq.com - May 9 at 6:32 PM |
| Nevro Corp. Just Tumbled By As Much As 12% -- Here's Why
finance.yahoo.com - May 9 at 6:32 PM |
| Medtech Player Losses Double That Of Views; Shares Tumble
finance.yahoo.com - May 9 at 6:32 PM |
| Nevro Corp (NVRO) Releases Quarterly Earnings Results, Misses Expectations By $0.24 EPS
www.americanbankingnews.com - May 9 at 4:02 PM |
| Nevro Corp (NVRO) Rating Reiterated by Northland Securities
www.americanbankingnews.com - May 9 at 11:32 AM |
 | B. Riley Downgrades Nevro Corp (NVRO) to Neutral Citing Slower US-Based Revenue Growth
www.streetinsider.com - May 9 at 11:26 AM |
| Nevro Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 6:23 PM |
 | Nevro reports 1Q loss
marketbeat.com - May 8 at 4:34 PM |
| Medical Product Q1 Earnings on May 8: ITGR, OPK & More
finance.yahoo.com - May 5 at 7:13 PM |
| Nevro Corp (NVRO) Receives Media Impact Score of -0.08
www.americanbankingnews.com - May 4 at 12:08 PM |
| Rami Elghandour Sells 10,000 Shares of Nevro Corp (NVRO) Stock
www.americanbankingnews.com - May 3 at 7:00 PM |
| Michael F. Demane Sells 29,800 Shares of Nevro Corp (NVRO) Stock
www.americanbankingnews.com - May 3 at 6:56 PM |
| Nevro to Present at the Bank of America Merrill Lynch 2017 Health Care Conference - Yahoo Finance
finance.yahoo.com - May 2 at 4:44 PM |
| Nevro to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 2 at 4:44 PM |
| Nevro Corp. – Value Analysis (NYSE:NVRO) : May 1, 2017
finance.yahoo.com - May 1 at 5:52 PM |
| Nevro Corp (NVRO) Earning Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 30 at 9:40 AM |
| Nevro Corp. breached its 50 day moving average in a Bullish Manner : NVRO-US : April 28, 2017
finance.yahoo.com - April 28 at 8:46 AM |
| $68.09 Million in Sales Expected for Nevro Corp (NVRO) This Quarter
www.americanbankingnews.com - April 26 at 12:16 PM |
| Nevro to Report Operating Results for the First Quarter 2017
finance.yahoo.com - April 25 at 5:43 AM |
| -$0.26 EPS Expected for Nevro Corp (NVRO) This Quarter
www.americanbankingnews.com - April 24 at 4:24 PM |
| Nevro Corp (NVRO) Earns Daily Coverage Optimism Score of -0.20
www.americanbankingnews.com - April 24 at 2:01 PM |
| ETFs with exposure to Nevro Corp. : April 21, 2017
finance.yahoo.com - April 21 at 6:48 PM |
| Nevro Corp (NVRO) Receiving Somewhat Negative Press Coverage, Analysis Shows
www.americanbankingnews.com - April 21 at 5:48 PM |
| Nevro Corp (NVRO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 17 at 10:14 AM |
| Nevro Corp (NVRO) Receiving Somewhat Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 15 at 2:55 PM |
| Nevro Becomes Oversold (NVRO)
www.nasdaq.com - April 12 at 7:52 PM |
| ETFs with exposure to Nevro Corp. : April 7, 2017
finance.yahoo.com - April 7 at 7:21 PM |
| Nevro Corp. breached its 50 day moving average in a Bearish Manner : NVRO-US : April 6, 2017
finance.yahoo.com - April 7 at 11:38 AM |
| Michael Enxing Sells 1,500 Shares of Nevro Corp (NVRO) Stock
www.americanbankingnews.com - April 5 at 8:52 PM |
| Insider Selling: Nevro Corp (NVRO) CFO Sells 30,000 Shares of Stock
www.americanbankingnews.com - April 5 at 8:04 PM |
| Nevro Corp (NVRO) Director Michael F. Demane Sells 22,200 Shares
www.americanbankingnews.com - April 5 at 8:03 PM |
 | Nevro: Increased Access To HF10 Therapy Will Power Stock Price
seekingalpha.com - March 29 at 7:37 PM |
| Nevro Corp (NVRO) Now Covered by Canaccord Genuity
www.americanbankingnews.com - March 29 at 8:47 AM |
| Canaccord Genuity Begins Coverage on Nevro Corp (NVRO)
www.americanbankingnews.com - March 29 at 8:41 AM |
| Commit To Purchase Nevro Corp At $75, Earn 10.2% Annualized Using Options
www.nasdaq.com - March 27 at 6:26 PM |
| Nevro Corp (NVRO) Now Covered by Analysts at Canaccord Genuity
www.americanbankingnews.com - March 23 at 2:10 PM |
 | Recent Developments in the Electrophysiology Markets
www.prnewswire.com - March 22 at 9:10 AM |
| Nevro Corp (NVRO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 21 at 12:34 PM |
 | Blog Coverage German and UK Courts Rule in Favor of Boston Scientifics' Patent Related Litigation with Edwards Lifesciences
www.baystreet.ca - March 10 at 9:22 AM |
| NEVRO CORP Financials
finance.yahoo.com - March 1 at 7:07 PM |
| Nevro Corp (NVRO) PT Raised to $110 at Leerink Partners - StreetInsider.com
www.streetinsider.com - February 24 at 8:55 AM |
| Edited Transcript of NVRO earnings conference call or presentation 23-Feb-17 9:30pm GMT
finance.yahoo.com - February 24 at 8:55 AM |
Nevro Corp (NVRO) Chart for Saturday, May, 27, 2017
